Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy
PURPOSE: Patients with hematologic malignancies are extremely vulnerable to financial toxicity (FT) because of the high costs of treatment and health care utilization. This pilot study identified patients at high...
Conclusions: Screening and intervention on FT for patients with hematologic malignancies is associated with increased quality of life and survival.
Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36068158/
Mantle cell lymphoma (MCL) accounts for nearly 2-6% of all non-Hodgkin lymphoma (NHL) cases, with a steady incidence increase over the past few decades. Although many patients achieve an adequate...
Relevance: In this report, we provide an updated literature review that covers recent clinical data about the safety and efficacy of novel therapies for the management of R/R MCL.
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2022.962552/full
Chronic lymphocytic leukemia (CLL), a highly heterogeneous B-cell malignancy, is characterized by tumor microenvironment disorder and T-cell immune dysfunction, which play a major role in the proliferation and survival of...
Conclusion/Relevance: In this review, we summarize the current evidence for the effects of ibrutinib on the tumor microenvironment and cellular immunity of patients with CLL, particularly for the behavior and function of T cells, explore its potential mechanisms, and provide a basis for the clinical benefits of long-term ibrutinib treatment and...
Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421985/
Inactivating mutations in Bruton's tyrosine kinase ( BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor‐treatment naïve patients. Here, we report...
Conclusion/Relevance: Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2...
A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421949/
Jorge J. Castillo, 1 , 2 Shayna Sarosiek, 1 , 2 Catherine A. Flynn, 1 Carly Leventoff, 1 Megan Little, 1 Timothy White, 1 Kirsten Meid, 1 and Steven P....
Relevance: The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib.
-
Leukemia and Lymphoma Connect3yrKey Points • Source: EJHaem • Relevance: “The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients Show More